The solubility and dissolution rate of pravastatin, a drug used for the treatment of hyperlipidaemia. Pravastatin is a selective competitive inhibitor of HMG Co A reductase. However its absolute bioavailability is 5%. To increase the solubility of drug solid dispersion was prepared. Solid dispersion preliminary solubility analysis was carried out for the selection of the carrier and solid dispersion was prepared with Hydroxy Propyl Methyl Cellulose (HPMC) and Methyl Cellulose (MC). These solid dispersions were analyzed for the solubility and in-vitro dissolution profile solid dispersion of drug with polymer has shown enhanced solubility with improved dissolution rate. Further FTIR, X-Ray studies were carried out. Solid dispersion prepared with polymer in 1:5 ratios shows the presence of amorphous form confirmed by the characterization study. The present investigations showed that solubility of Pravastatin sodium was markedly increased by its solid dispersion using PVP K30 as carrier. The formulation SDF8 containing (1:8) shows highest dissolution rate. Hence the solid dispersion a way is useful technique in providing fastest onset of action of Pravastatin sodium as well as enhanced dissolution rate. The study also shows that dissolution rate of pravastatin can be enhanced to considerable extent by solid dispersion technique with Polymer

The object of the present investigation is to be screening of aqueous extract of Tagetes erecta (200 mg/kg and 400 mg/kg) administered by orally were selected on anti-diarrhoeal action. In this investigation, screening by castor oil induced diarrhoeal model, charcoal meal test model and PGE2 induced test model also dose of standard drugs is Loperamide (2 mg/kg) as well as atropine (0.1 mg/kg) were used in this study. Plant extract in dose of 200 and 400 mg/kg used followed by Phytochemical and acute toxicity study. In results of extract formed significant anti-diarrhoeal active against castor oil induced diarrhoea, charcoal meal test as well PGE2 induced diarrhoea. It also cause dose linked anti-diarrhoeal result. Results propose that it may proceed centrally and may inhibition of PGE2 to give anti-diarrhoeal action. Result of charcoal meal test also suggests its anti-muscarnic activity

A sustained release system for Valsartan designed to increase its residence time in the stomach without contact with the Microspheres was achieved through the preparation of floating Microspheres by the Modified Emulsion solvent Diffusion method. In the present study attempt has been made to develop sustained released drug delivery system by formulating the floating Microspheres of Valsartan using psyllium husk powder as a natural polymer which is biodegradable, biocompatible, nontoxic, economically cheap cost, devoid of adverse and side effects and easily availability. Valsartan N-(1-oxopentyl)-N- [[2-(1H-tetrazol-5-yl) [1,1’-biphenyl] -4[ -yl] methyl] L Valine used as an Anti-hypertensive agent. The 12 batches of floating Microspheres (VF1 to VF12) were formulated by Modified Emulsion solvent Diffusion method using different ratio of polymers like Psyllium husk power, HPMC K4M and Carbopal. The formulated Microspheres were evaluated by means of different parameters like shape and density of Microsphere, drug content uniformity, Invitro buoyancy, swelling Index, Invitro dissolution studies. The formulation VF7 has better sustained release when compared other formulations, hence we conclude that the combination of Psyllium husk powder, HPMC K4M shows better Gastric retention time which sustains the release of the dosage form

The oral administration of Celecoxib causes gastrointestinal ulcers and bleeding in chronic use. Due to gastrointestinal bleeding it may cause anaemia. Also, use of Celecoxib is limited by its poor solubility and low bioavailability. Thus, the present study aimed at design and development of a drug delivery system which could enhance the solubility of Celecoxib. Lipid based drug delivery has attracted much attention during recent years as innovative strategy to overcome insufficient bioavailability of hydrophobic drugs. S-SLN can also offer better patient compliance. One of the most popular and commercially viable formulation approaches for solving these problems is SLN which have been shown to be reasonably successful in improving the oral bioavailability of various poorly water-soluble SLN are isotropic mixtures of drug, oil/lipid, surfactant, and/or cosurfactant, which form fine emulsion/lipid droplets, ranging in size from approximately 100 nm on dilution with physiological fluid. The drug, therefore, remains in solution in the gut, avoiding the dissolution step that frequently limits the absorption rate of hydrophobic drugs from the crystalline state SLN can be optimized with the help of phase diagram, when such a system is released in the lumen of the GIT, it disperses to form a fine emulsion with the aid of GIT fluid

Self-micro emulsifying drug delivery system (SMEDDS) is a promising system for the Biopharmaceutics Classification System (BCS) class II drugs. The current research aimed to improve the dissolution of poorly water-soluble anti-diabetic drug simvastatin by formulating it in SMEDDS. Liquid SMEDDS of simvastatin were formulated with Capmul MCM C8 and oleic acid as oil phase, Cremophor RH 40 and Tween 80 as surfactant phase, and Transcutol P as cosurfactant phase after screening various vehicles. The prepared formulations were evaluated for self-emulsifying ability and phase diagram was constructed to optimize the system. These systems were further characterized for globule size, effect of pH and robustness, zeta potential, drug content, viscosity, self-emulsification time, poly dispersity index, % transmittance, thermodynamic stability, surface morphology, and drug release. The system was robust to different pH media and dilution volumes. The optimized system possessed a mean globule size of 122.2 nm, zeta potential around - 22.9 mV, drug content 99.66 ± 0.47%, viscosity 0.8874 ± 0.026 cP, emulsification time 38 s, poly dispersity index value of 0.5, and transmittance value of 99.3 ± 0.6%. Drug release in hydrochloric acid buffer pH 2 was found to be 99.35 ± 0.38%. More than three-fold increase in dissolution characteristics of simvastatin in SMEDDS was observed as compared to pure and marketed formulation. Liquid SMEDDS filled in hard gelatin capsule (HGC) shell was found to be compatible. Stability studies show there was no sign of phase separation or precipitation and no change in drug content was observed.